Medication and dosage considerations in the prophylaxis and treatment of high-altitude illness.
about
Interventions for preventing high altitude illnessInterventions for treating high altitude illnessDexamethasone blocks the systemic inflammation of alveolar hypoxia at several sites in the inflammatory cascadeReturn to activity at altitude after high-altitude illness.Physiological variables associated with the development of acute mountain sickness at the South PoleJourneys to high altitude--risks and recommendations for travelers with preexisting medical conditions.Pulmonary vasodilation by acetazolamide during hypoxia: impact of methyl-group substitutions and administration route in conscious, spontaneously breathing dogs.Short-term responses of the kidney to high altitude in mountain climbers.Diabetes, trekking and high altitude: recognizing and preparing for the risks.Interventions for preventing high altitude illness: Part 1. Commonly-used classes of drugs.Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors.Anuric Acute Kidney Injury Induced by Acute Mountain Sickness Prophylaxis With Acetazolamide.High-altitude medicines: a short-term genotoxicity study.Acetazolamide suppresses the prevalence of augmented breaths during exposure to hypoxia.Comparison of the pharmacokinetics of sulfamethoxazole in native Han and Tibetan male Chinese volunteers living at high altitude.An Approach to Children with Pulmonary Edema at High AltitudeContinuous positive airway pressure increases haemoglobin O2 saturation after acute but not prolonged altitude exposureTravelers with underlying medical conditions
P2860
Q24200658-B5588DF6-8023-4816-A98D-6BA9BEDC9E3FQ24203956-40FAE8F5-E85B-4C34-A23A-7082430C15DAQ28386843-58AB17FD-4837-461B-B1D9-75CA15021F2BQ36242100-D13808BD-D9E8-4EDD-9DE1-E54CF99A4DEAQ37029950-52D88AD9-EE62-4C40-A79A-AD691B062D33Q37674872-BE68BCF4-B586-4138-8F8F-B1057E4E3E4CQ37679362-1EB7C1C3-F4F1-4B05-9878-864FF3E00325Q38092654-BA7C37F7-42D9-4D39-9464-584F7268F8ECQ38473156-B03A157B-E744-4EF9-B52E-F71438AB536AQ38707663-A4BCC369-A2ED-4B9B-8CF6-88E2682D1334Q38733892-2D4E3C27-33C7-4B6B-828F-2AA1F3C9A27BQ42916844-F420DB07-1C17-4E1E-A711-9724E0BE6759Q43053704-CA44C986-F6EB-4D85-A879-03AB89E5E3BEQ45983943-98B25745-48B6-4062-8389-7C30D68CC2D2Q50514196-92B059EA-8246-4717-924B-7FB5333D8118Q57093095-B8C88EBA-092C-4F24-A23F-2D5B82832341Q57101837-3B84E54B-CBEF-4AC0-932F-298C2D6B6929Q57601485-220DC3FA-E27A-4E16-9CBC-5C97FAC83473
P2860
Medication and dosage considerations in the prophylaxis and treatment of high-altitude illness.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Medication and dosage consider ...... ment of high-altitude illness.
@ast
Medication and dosage consider ...... ment of high-altitude illness.
@en
Medication and dosage consider ...... ment of high-altitude illness.
@nl
type
label
Medication and dosage consider ...... ment of high-altitude illness.
@ast
Medication and dosage consider ...... ment of high-altitude illness.
@en
Medication and dosage consider ...... ment of high-altitude illness.
@nl
prefLabel
Medication and dosage consider ...... ment of high-altitude illness.
@ast
Medication and dosage consider ...... ment of high-altitude illness.
@en
Medication and dosage consider ...... ment of high-altitude illness.
@nl
P356
P1433
P1476
Medication and dosage consider ...... ment of high-altitude illness.
@en
P2093
Andrew M Luks
Erik R Swenson
P304
P356
10.1378/CHEST.07-1417
P407
P577
2008-03-01T00:00:00Z